According to the recommendations from National Comprehensive Cancer Network (NCCN) guidelines, all patients diagnosed with adenocarcinoma, and selected patients with squamous lung cancer should receive driver gene test for detecing relevant mutations, including epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS proto-oncogene 1 (ROS1) rearrangements, and V-raf murine sarcoma viral oncogene homologB1 (BRAF) V600E mutations, as well as expression level of the protein programmed death ligand 1 (PD-L1). The gene discussed is ALK; the disease is adenocarcinoma.